Conclusion: Patients considering semaglutide should discuss their full medical history with their healthcare provider to determine if it is an appropriate and safe option for them.
We review lab work and identify any health gaps that may accompany your weight management plan
This paradoxical finding underscores the complexity of SEMs interaction with the brain and challenges the conventional understanding of its BBB permeability
Consult your healthcare provider if you have concerns
Semaglutide belongs to a class called GLP-1 receptor agonists the same category that includes Ozempic, Wegovy, and even tirzepatide medications like Mounjaro and Zepbound
Who Might Benefit From Dual-Compound Semaglutide and Tirzepatide Therapy Patients who benefit most from dual-compound GLP-1 protocols typically have high baseline weight, comorbid type 2 diabetes, a family history of metabolic disease, or prior inadequate response to single-agent therapy